-
Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy Clin. Lung Cancer (IF 3.6) Pub Date : 2024-03-16 Trie Arni Djunadi, Youjin Oh, Jeeyeon Lee, Jisang Yu, Liam Il-Young Chung, Yeunho Lee, Leeseul Kim, Timothy Hong, Soowon Lee, Zunairah Shah, Joo Hee Park, Sung Mi Yoon, Young Kwang Chae
Immune checkpoint inhibitors (ICIs) may be associated with hyperprogressive disease (HPD). However, there is currently no standardized definition of HPD, with its risk factors and clinical implications remaining unclear. We investigated HPD in lung cancer patients undergoing immunotherapy, aiming to redefine HPD, identify risk factors, and assess its impact on survival. Clinical and radiologic data
-
Neutrophil-to-lymphocyte ratio and risk of nodal metastasis in early-stage lung adenocarcinoma: a brief report from a multicentric analysis Clin. Lung Cancer (IF 3.6) Pub Date : 2024-03-15 Filippo Tommaso Gallina, Marco Chiappetta, Riccardo Tajè, Daniele Forcella, Carolina Sassorossi, Maria Teresa Congedo, Jessica Evangelista, Isabella Sperduti, Filippo Lococo, Federico Cappuzzo, Enrico Melis, Stefano Margaritora, Francesco Facciolo
[Display omitted]
-
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study Clin. Lung Cancer (IF 3.6) Pub Date : 2024-03-15 Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Dmytro Trukhin, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng-Ta Yang, Luiz Henrique Araujo, Haruhiro Saito, Niels Reinmuth, Milena Kohlmann, Caitlin Lowery, Helen Mann, Solange Peters, Tony S. Mok, Melissa L. Johnson
In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and platinum-based chemotherapy (T+D+CT) significantly improved overall survival (OS; hazard ratio [HR] 0.77 [95% confidence interval {CI} 0.65–0.92]; =.0030) and progression-free survival (PFS) versus chemotherapy alone (CT) in patients with metastatic NSCLC (mNSCLC), leading to approval for this regimen. We report outcomes by
-
Brief Report: Impact of reflex testing on tissue-based molecular genotyping in patients with advanced non-squamous non-small cell lung cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2024-03-12 Melina E. Marmarelis, Dylan G. Scholes, Cindy M. McGrath, Salvatore F. Priore, Jacquelyn J. Roth, Michael Feldman, Jennifer J.D. Morrissette, Leslie Litzky, Charu Deshpande, Jeffrey C. Thompson, Abigail Doucette, Peter E. Gabriel, Lova Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Erica L. Carpenter, Charu Aggarwal
DNA-based molecular genotyping is an essential component of management of patients with metastatic non-squamous non-small cell lung cancer upon initial diagnosis. We hypothesized that implementation of a reflex testing pathway initiated by pathologists would ease logistical barriers and challenges in ordering tissue-based DNA-based molecular genotyping. We conducted a retrospective cohort study at
-
Lung Cancer Survival Trends in the Veterans Health Administration Clin. Lung Cancer (IF 3.6) Pub Date : 2024-03-02 Drew Moghanaki, James Taylor, Alex K. Bryant, Lucas K. Vitzthum, Nikhil Sebastian, David Gutman, Abigail Burns, Zhonglu Huang, Jennifer A. Lewis, Lucy B. Spalluto, Christina D. Williams, Donald R. Sullivan, Christopher G. Slatore, Madhusmita Behera, William A. Stokes
Lung cancer survival is improving in the United States. We investigated whether there was a similar trend within the Veterans Health Administration (VHA), the largest integrated healthcare system in the United States. Data from the Veterans Affairs Central Cancer Registry (VACCR) were analyzed for temporal survival trends using Kaplan-Meier (K-M) estimates and linear regression. 54,922 Veterans were
-
Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer – Results from a Single Institution Study Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-24 Benjamin George, Atallah Baydoun, Samar Bhat, Lauryn Bailey, Theodore Arsenault, Yilun Sun, Yuxia Zhang, Yiran Zheng, Prashant Vempati, Tarun Podder, Tithi Biswas
[Display omitted]
-
QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-17 Bilal Khokhar, Beatrice Chiang, Kristy Iglay, Kamika Reynolds, Nidia Rodriguez-Ormaza, William Spalding, Eric Freedland
[Display omitted]
-
Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-17 Ji Eun Park, Kyung Soo Hong, Sun Ha Choi, Shin Yup Lee, Kyeong-Cheol Shin, Jong Geol Jang, Yong Shik Kwon, Sun Hyo Park, Keum-Ju Choi, Chi Young Jung, Jung Seop Eom, Saerom Kim, Hee Yun Seol, Jehun Kim, Insu Kim, Jin Han Park, Tae Hoon Kim, June Hong Ahn
Durvalumab consolidation is now the standard-of-care after concurrent chemoradiotherapyin patients with unresectable stage III non-small-cell lung cancer. Our multicenter retrospective study of 286 patients showed that elderly patients had similar survival outcomes but experienced more adverse events (AEs) than younger patients. Careful patient selection and AE monitoring are needed during durvalumab
-
Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-15 Ben Ponvilawan, Himil Mahadevia, Hana Qasim, Parth Sharma, Dhruv Bansal, Janakiraman Subramanian
Recent randomized controlled trials (RCTs) have shown that neoadjuvant or adjuvant treatment with immune checkpoint inhibitors (ICIs) and chemotherapy improves survival outcomes for patients with resectable non-small cell lung cancer (NSCLC). We conducted this meta-analysis of RCTs to determine the survival benefits according to the clinical characteristics and treatment sequence. All phase II or III
-
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-13 Angelica D'Aiello, Brendon Stiles, Nitin Ohri, Benjamin Levy, Perry Cohen, Balazs Halmos
Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab
-
artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of first-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-08 Yusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, Yoko Tsukita, Shuji Murakami, Yukio Hosomi, Yuichi Tambo, Yoshihito Kogure, Hiroshige Yoshioka, Motohiro Tamiya, Kiichiro Ninomiya, Eiji Iwama
: Thymic carcinoma is a rare cancer with an aggressive clinical presentation and no organotypic symptoms. Despite using platinum-based chemotherapy as first-line treatment, the prognosis remains poor, necessitating a novel therapeutic strategy.
-
A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-08 Yingxi Wu, Yuhua Zhao, Yufeng Wu, Haiyang Chen, Shuxiang Ma, Qiming Wang
To analyze the factors associated with EGFR mutated lung cancer with leptomeningeal metastasis (LM) in the real world that affect the prognosis of patients. The clinical data of 123 patients with advanced EGFR mutated lung cancer combined with LM treated at Henan Cancer Hospital and confirmed by histology between January 2016 and December 2020 were retrospectively collected, and all patients were followed
-
Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-02 Yusuke Okuma, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date
In advanced non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations, those with impaired performance status (PS) treated with EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated comparable activities to good-PS patients. Due to the limited sample size and inclusion of older adult patients with good PS, these findings may not accurately depict the
-
Improvement of Prediction Performance for Radiation Pneumonitis by Using 3-Dimensional Dosiomic Features Clin. Lung Cancer (IF 3.6) Pub Date : 2024-02-01 AiHui Feng, Ying Huang, Ya Zeng, Yan Shao, Hao Wang, Hua Chen, HengLe Gu, YanHua Duan, ZhenJiong Shen, ZhiYong Xu
Patients with early non-small-cell lung cancer (NSCLC) have a relatively long survival time after stereotactic body radiation therapy (SBRT). Predicting radiation-induced pneumonia (RP) has important clinical and social implications for improving the quality of life of such patients. This study developed an RP prediction model by using 3-dimensional (3D) dosiomic features. The model can be used to
-
A Case of ROS1-Fusion Non-Small Cell Lung Cancer with Acquired BRAF Mutation Developing Unusual Skin Metastasis Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-30 Wahed A. Firoz, Fatma Sen, Maija Kiuru, Victor Huang, Jonathan W. Riess
Abstract not available
-
Clinical significance of preserving pulmonary function after lung resection in early-stage non-small cell lung cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-26 Norifumi Tsubokawa, Takahiro Mimae, Takeshi Mimura, Atsushi Kamigaichi, Makoto Fujiwara, Nobutaka Kawamoto, Yoshihiro Miyata, Morihito Okada
-
Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE trial Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-28 Taichi Matsubara, Masafumi Yamaguchi, Mototsugu Shimokawa, Isamu Okamoto
Introduction Atezolizumab following platinum chemotherapy and complete pulmonary resection has become the new standard of adjuvant care for patients with stage II–III non-small cell lung cancer (NSCLC) expressing programmed death-ligand 1 (PD-L1). However, the efficacy and safety of postoperative adjuvant therapy and subsequent atezolizumab in patients aged 75 and older have not been established. Methods
-
A multi-institutional, randomized, phase III trial comparing anatomical segmentectomy and lobectomy for clinical stage IA3 pure-solid non-small cell lung cancer: West Japan Oncology Group Study WJOG16923L (STEP UP trial) Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-26 Atsushi Kamigaichi, Akira Hamada, Masahiro Tsuboi, Kenichi Yoshimura, Isamu Okamoto, Nobuyuki Yamamoto, Yasuhiro Tsutani
Introduction Although the standard treatment for patients with resectable early-stage non-small-cell lung cancer (NSCLC) is pulmonary lobectomy, recent clinical trials have demonstrated the efficacy of anatomical segmentectomy for small-sized early-stage NSCLC measuring ≤2 cm. Segmentectomy is gaining attention as an alternative procedure to lobectomy for early-stage NSCLC. Patients and Methods In
-
Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-29 Erik Wu, Joseph Reznicek, Anjana V. Yeldandi, Jyoti D. Patel, David D. Odell
Primary lymphoepithelial carcinoma (LEC) of the lung is an extremely rare subset of non-small cell lung cancer (NSCLC) with less than 500 documented cases since its identification in 1987. A vast majority of these cases occur in east or southeast Asia and have been associated with Epstein-Barr Virus (EBV). While localized disease has been managed via surgical resection or resection followed by adjuvant
-
HER2-Mutant Advanced and/or Metastatic Non–Small Cell Lung Cancer: a US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-18 Sarah Waliany, Joel W. Neal, Nicole Engel-Nitz, Clara Lam, Feng Lin, Leah Park, Lisa Le, Misako Nagasaka
Background Real-world data for advanced/metastatic non-small cell lung cancer (NSCLC) with mutations in human epidermal growth factor 2 (HER2) are scarce. We aimed to assess treatment patterns and outcomes among patients with HER2-mutant advanced/metastatic NSCLC. Patients and methods This retrospective nationwide electronic health record study evaluated patient characteristics, treatment patterns
-
-
-
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-06 Delvys Rodriguez-Abreu, Joaquim Bosch-Barrera, Jhanelle E. Gray, Myung-Ju Ahn, Melissa Johnson, Xinwei Yu, Saad Mohammad, Xueying Chen, Trever Todd, Jongseok Kim, Martin Reck
Introduction Dual inhibition with a T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) plus programmed death (ligand)-1 (PD[L]-1) inhibitors, with or without chemotherapy, is an emerging therapeutic strategy in metastatic non-small cell lung cancer (mNSCLC). The STAR-121 (NCT05502237) phase III, global, randomized, open-label study will investigate first-line domvanalimab (anti-TIGIT)
-
Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief Report Clin. Lung Cancer (IF 3.6) Pub Date : 2024-01-02 Fatemeh Ardeshir-Larijani, Rohan Maniar, Subir Goyal, Patrick J Loehrer, Tieying Hou, Victoria DeBrock, Hector Mesaresul
Objective To expand prognostic markers and therapeutic options for thymus epithelial tumors (TETs), we evaluated several potential targets with existing experimental and FDA-approved therapies in a large tissue microarray (TMA). Methods A TMA consisting of 90 malignant tumors and 7 normal adult thymus samples were assembled and evaluated for the expression of GLUT1, Trop2, PSMA, ROS1, ALK, HER2, and
-
So Now We Know – Reflections on the Extent of Resection for Stage I Lung Cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-28 FC Detterbeck, S Ely, BV Udelsman, JD Blasberg, DJ Boffa, AP Dhanasopon, VJ Mase, GA Woodard
-
Predictors of Early Hospice or Death in Patients with Inoperable Lung Cancer Treated with Curative Intent Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-27 Siddharth Ramanathan, Kimberly A Hochstedler, Anna M Laucis, Benjamin Movsas, Craig W Stevens, Larry L Kestin, Michael M Dominello, Inga S Grills, Martha Matuszak, James Hayman, Peter A Paximadis, Matthew J Schipper, Shruti Jolly, Thomas P Boike
Introduction Treatment for inoperable stage II-III non-small cell lung cancer (NSCLC) involves chemo-radiotherapy (CRT). However, some patients transition to hospice or die early during their treatment course. We present a model to prognosticate early poor outcomes in NSCLC patients treated with curative-intent CRT. Methods and Materials Across a statewide consortium, data was prospectively collected
-
To crush or not to crush: administering dabrafenib and trametinib through a nasogastric tube in a critically ill patient with non-small cell lung cancer – A case report and review of literature of targeted therapies given through enteral feeding tubes Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-27 Charley Jang, Sally CM Lau, Vamsidhar Velcheti
Up to 71% of lung cancer patients admitted to the ICU are newly diagnosed. The decision to initiate cancer directed treatments in lung cancer patients admitted to the ICU remains complex. For those with identified oncogene driver mutations, targeted therapies with rapid and high response rates are attractive treatment options. However, mechanically ventilated patients face additional barriers in which
-
Plunging into the PACIFIC: Outcomes of Patients with Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-22 Adam Barsouk, Cole Friedes, Michelle Iocolano, Abigail Doucette, Roger B. Cohen, Kyle W. Robinson, Christopher A. D'Avella, Melina E. Marmarelis, John A. Kosteva, Aditi P. Singh, Christine A. Ciunci, William P. Levin, Keith A. Cengel, Jeffrey D. Bradley, Steven J. Feigenberg, Lova Sun, Charu Aggarwal, Corey J. Langer, Nikhil Yegya-Raman
Background Immune checkpoint inhibitor (ICI) consolidation following concurrent chemoradiotherapy (CRT) substantially improved PFS and OS in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI. Methods In this single-institution, retrospective analysis, we compared treatment outcomes for patients with unresectable KRAS
-
APOLLO 11 Project, Consortium in advanced lung cancer patients treated with innovative therapies: Integration of real-world data and translational research. Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-22 Arsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Giulio Metro, Giulia Galli, Francesco Agustoni, Carminia Maria Della Corte, Andrea Spagnoletti, Claudia Giani, Roberto Ferrara, Claudia Proto, Marta Brambilla, Andra Diana Dumitrascu, Alessandro Inno, Diego Signorelli, Elio Gregory Pizzutilo, Matteo Brighenti, Federica Biello, Andrea Vingiani
Introduction Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been aimed at indentifying biomarkers able to predict benefit from these therapies and create a prediction model of response, despite this there
-
Pembrolizumab plus chemotherapy per PD-L1 stratum in patients with metastatic non-small cell lung cancer: real-world effectiveness versus trial efficacy Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-20 M.V. Verschueren, B.J.M. Peters, L.T. Bloem, V.R. Kruik, E.B. Uitvlugt, A.R. Bijsmans, A.C.G. Egberts, E.M.W. van de Garde
Background Clinical trial efficacy and real-world effectiveness of oncological treatments can differ. This study assessed the real-world survival outcomes of first-line pembrolizumab plus chemotherapy per PD-L1 stratum in patients with metastatic non-small cell lung cancer (mNSCLC) and compared them to clinical trial results. Methods All patients with non-squamous and squamous mNSCLC who received first-line
-
Brief Report: Non-Malignant Resection Among Individuals with Screening-Detected vs. Incidental Lung Nodules: Variation in Lung Nodule Management Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-19 Brian M. Till, Tyler Grenda, Taylor Tidwell, Baylor Wickes, Christine Shusted, Brooke Ruane, Olugbenga Okusanya, Nathaniel R. Evans, Julie A. Barta
BACKGROUND At present it remains unknown whether individuals with lung nodules detected through Lung Cancer Screening (LCS) Programs vs. individuals with incidentally identified lung nodules experience different clinical and surgical outcomes relative to their nodule detection status. We aimed to characterize baseline characteristics, lung nodule evaluation strategies, and non-malignant resection (NMR)
-
Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-19 Yohann Pilon, Merav Rokah, Joseph Seitlinger, Boris Sepesi, Roni F. Rayes, Jonathan Cools-Lartigue, Sara Najmeh, Christian Sirois, David Mulder, Lorenzo Ferri, Bassam Abdulkarim, Nicole Ezer, Richard Fraser, Sophie Camilleri-Broët, Pierre-Olivier Fiset, Annick Wong, Shelly Sud, Adrian Langleben, Jason Agulnik, Carmela Pepe, Jonathan D. Spicer
Background Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III NSCLC and numerous trials investigating novel agents are underway. However, significant concerns exist around the feasibility and safety of offering curative surgery to patients treated within such pathways. The goal in this study was to evaluate the impact of a transition
-
The clinical outcomes of thoracoscopic versus open lobectomy for non-small-cell lung cancer after neoadjuvant therapy: A multi-center retrospective cohort study Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-16 Jinlin Cao, Chong Zhang, Xun Zhang, Lunxu Liu, Xiaofei Li, Jianxing He, Lin Xu, Xiangning Fu, Yang Liu, Deruo Liu, Jian Hu, Luming Wang
Background The safety and efficacy of video-assisted thoracic surgical (VATS) versus open lobectomy for non-small-cell lung cancer (NSCLC) following neoadjuvant therapy remained controversial. The aim of this study was to compare the outcomes of VATS with those of open lobectomy for NSCLC after neoadjuvant therapy. Methods Patients who had undergone VATS or open lobectomy for NSCLC following neoadjuvant
-
In depth analysis of lorlatinib related neurocognitive adverse events in patients with non-small cell lung cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-13 J.J.A.O. Schoenmaekers, J. Dijkstra, A.J. van der Wekken, M.S. Paats, M.P.G. Broen, L. Brandts, A-M.C Dingemans, L.E.L. Hendriks
Introduction . Lorlatinib is a potent, brain penetrant, next generation ALK/ROS1 TKI, with high response rates and durable responses, including the brain. However, a significant drawback is the manifestation of neurocognitive adverse events (NCAEs). Despite being generally low-grade in severity, these NCAEs can be physically and mentally disabling. Extensive neurocognitive testing in this group of
-
Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-13 Laurent Mathiot, Benoit Nigen, Thomas Goronflot, Sandrine Hiret, Ludovic Doucet, Elvire Pons-Tostivint, Jaafar Bennouna, Marc G. Denis, Guillaume Herbreteau, Judith Raimbourg
Background Prognostic impact of TP53 mutations in advanced or metastatic non-squamous non-small-cell lung cancer (nsNSCLC) patients treated with chemotherapy and/or immune checkpoint inhibitors (ICI) remains unclear. Materials and methods We retrospectively collected data from patient with nsNSCLC treated in first line from January 2018 to May 2021. Patient were separated into two groups according
-
HIV associated Lung Cancer - Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-12 Ayse Ece Cali Daylan, Catarina Martins Maia, Shirin Attarian, Xiaoling Guo, Mindy Ginsberg, Enrico Castellucci, Rasim Gucalp, Missak Haigentz, Balazs Halmos, Haiying Cheng
Objectives Lung cancer contributes significantly to morbidity and mortality in people with HIV (PWH). We study the clinicopathologic characteristics and immune microenvironment in HIV associated lung cancer. Material and Methods Clinicopathological characteristics including immunotherapy outcomes were collected for 174 PWH diagnosed with lung cancer. Immunohistochemical staining for PD-L1, CD4 and
-
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-07 Yun Fan, Alexander Drilon, Chao-Hua Chiu, Herbert H.F. Loong, Salvatore Siena, Maciej Krzakowski, Rafal Dziadziuszko, Harald Zeuner, Cloris Xue, Matthew G. Krebs
Abstract not available
-
Trial design and optimal determination of CNS activity of small molecule targeted therapy in NSCLC Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-05 Elaine M. Jennings, D. Ross Camidge, Shirish Gadgeel, Scott Barker
Central nervous system (CNS) metastases are frequently diagnosed in patients with non-small cell lung cancer (NSCLC). Only recently, clinical trials are broadening eligibility to include patients with brain metastases, offering the potential for some assessment of CNS efficacy to be made. In this work we aim to review the available information on the activity of small molecule targeted drugs for advanced
-
Efficacy of Mobocertinib and Amivantamab in Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertions Previously Treated with Platinum-based Chemotherapy: An Indirect Treatment Comparison Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-04 Sai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M. Lin, Jin-liern Hong, Min Tan, Irina Proskorovsky, Luis Hernandez, Shu Jin, Pingkuan Zhang, Jianchang Lin, Jyoti Patel, Danny Nguyen, Joel W. Neal
Objectives Exon 20 insertions (ex20ins) mutations of the EGFR gene account for 1-2% of all non-small cell lung cancers (NSCLC). Targeted therapies have been developed to treat this cancer type but have not been studied in head-to-head trials. Our objective was to use a matching-adjusted indirect comparison (MAIC) to assess the efficacy of mobocertinib and amivantamab in patients with NSCLC EGFR ex20ins
-
Detection of Circulating Tumor DNA after Stereotactic Ablative Radiotherapy in Patients with Unbiopsied Lung Tumors (SABR-DETECT) Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-01 Saurav Verma, Sympascho Young, Thomas A.C. Kennedy, Ilda Carvalhana, Morgan Black, Kathie Baer, Emma Churchman, Andrew Warner, Alison L. Allan, Jesus Izaguirre-Carbonell, Harmeet Dhani, Alexander V. Louie, David A. Palma, Daniel A. Breadner
For patients with stage I/IIA non-small cell lung cancer (NSCLC), surgical resection is the standard treatment. However, some of these patients are not candidates for surgery or refuse a surgical option. Definitive stereotactic ablative radiotherapy (SABR) is a standard approach in these patients. Approximately 15% of patients undergoing SABR for localized NSCLC will experience a recurrence within
-
Clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small cell lung cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-12-01 Paola Ghanem, Joseph C. Murray, Melinda Hsu, Matthew Z Guo, David S. Ettinger, Josephine Feliciano, Patrick Forde, Christine L. Hann, Vincent K. Lam, Benjamin Levy, Valsamo Anagnostou, Julie R. Brahmer, Kristen A. Marrone
Objectives : Understand from a real-world cohort the unique clinical and genomic determinants of a durable response to immune checkpoint inhibitors (ICIs). Materials and Methods : This is a retrospective study of patients with NSCLC who received any ICI-based regimen as first or second line therapy. Long-term responders (LTR) achieved an overall survival (OS) ≥ 3 years from time of treatment start
-
A multicentre study assessing the real-world use and effectiveness of first-line chemotherapy plus immunotherapy in advanced Small Cell Lung Cancer (SCLC) patients Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-23 Porte Marie, Vaudron Adrien, Crequit Perrine, Vaugier Loig, Chatellier Thierry, Fronteau Clémentine, Raimbourg Judith, Goronflot Thomas, Bennouna Jaafar, Pons-Tostivint Elvire
Background First-line chemotherapy plus immunotherapy (CT-IO) have recently demonstrated survival benefit over CT alone in Extensive-Stage Small Cell Lung Cancer (ES-SCLC), based on randomized phase 3 studies. This retrospective multicentre study assessed the real-world use and effectiveness of CT-IO in ES-SCLC patients. Patients and Methods All newly diagnosed ES-SCLC patients from four French hospitals
-
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small Cell Lung Cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-21 Caressa Hui, Cesar Marquez, Brianna Lau, Millie Das, Nathaniel J. Myall, Mohana Roy, Heather A. Wakelee, Joel W. Neal, Nataliya Kovalchuk, Alex Chin, Maximilian Diehn, Billy W Loo Jr, Michael Xiang, Lucas K. Vitzthum, Lucas K. Vitzthum
Purpose/Objectives: Adoption of hypofractionated accelerated radiation therapy (HART) with concurrent chemotherapy has been limited by toxicity concerns. We aimed to describe outcomes of patients treated with HART and concurrent chemotherapy and to evaluate dosimetry to organs at risk to guide patient selection. Materials/Methods: We evaluated a retrospective cohort of NSCLC patients treated with concurrent
-
Advances in the diagnosis and treatment of advanced non-small cell lung cancer with EGFR exon 20 insertion mutation Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-23 Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
The discovery of epidermal growth factor receptor (EGFR) mutations has greatly changed the clinical outlook for patients with advanced non-small cell lung cancer (NSCLC). Unlike the most common EGFR mutations, such as exon 19 deletion (del19) and exon 21 L858R point mutation, EGFR exon 20 insertion mutation (EGFR ex20ins) is a rare mutation of EGFR. Due to its structural specificity, it exhibits primary
-
Association between Lung Immune Prognostic Index and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-22 Mariona Riudavets, Edouard Auclin, Miguel Mosteiro, Naomi Dempsey, Margarita Majem, Arsela Prelaj, Rafael López-Castro, Joaquim Bosch-Barrera, Sara Pilotto, Elena Escalera, Marco Tagliamento, Joaquin Mosquera, Gérard Zalcman, Frank Aboubakar Nana, Santiago Ponce, Víctor Albarrán-Artahona, Alessandro Dal Maso, Martina Spotti, Xabier Mielgo, Elodie Mussat, David Planchard
Introduction The LIPI, based on pre-treatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab consolidation outcomes in the locally advanced setting. Material and methods Multicentre retrospective study (330 patients)
-
-
-
Sterotactic Ablative radiotherapy in a Multicentric series of Oligometastatic SCLC: the SAMOS cohort Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-17 Paolo Borghetti, Giorgio Facheris, Patrizia Ciammella, Marco Galaverni, Lorenzo Granello, Vieri Scotti, Davide Franceschini, Andrea Romei, Niccolò Giaj Levra, Manuela Federico, Maria La Vecchia, Anna Merlotti, Matteo Sepulcri, Gaia Piperno, Giulia Marvaso, Nicola Simoni, Emanuele Alì, Antonio Pontoriero, Anna Cappelli, Valeria Dionisi, Marta Scorsetti
Aims SCLC is the most aggressive lung cancer histology with a 5-year OS <10%. At the diagnosis, almost two-thirds of the SCLC an Extended Disease presentation. Two randomized studies (CASPIAN and ImPower133) demonstrated an OS improvement, when immunotherapy was prescribed as maintenance therapy after standard chemotherapy. To date, SABR has had a limited indication in managing metastatic SCLC, although
-
ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated with Alectinib: A Case Report Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-17 Luis F. Gonzalez-Mosquera, Fawzi Abu Rous, Alexandra Rogers, Nicolina Smith, Gregory Goyert, Shirish Gadgeel
There are few reported cases of ALK gene rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC) during pregnancy. There is a lack of information on the safety of ALK inhibitors in pregnant patients. We present a 25-year-old African American woman who was diagnosed with metastatic ALK+ lung adenocarcinoma at 15 weeks of gestation. Treatment with alectinib was initiated at 18 weeks' gestation with resultant
-
Comments on "Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the “PACIFIC” Era" Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-14 Nitin Ohri, Neel P Chudgar, Marc Vimolratana, Haiying Cheng, Brendon Stiles
Abstract not available
-
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-08 Caressa Hui, Eleanor Brown, Samantha Wong, Millie Das, Heather Wakelee, Joel Neal, Kavitha Ramchandran, Nathaniel J. Myall, Daniel Pham, Lei Xing, Yong Yang, Nataliya Kovalchuk, Ying Yuan, Ying Lu, Michael Xiang, Alex Chin, Maximilian Diehn, Billy W Loo, Lucas K. Vitzthum
Introduction Prior attempts to escalate radiation dose for non-small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients. This phase I/II trial aims to evaluate a novel treatment approach where the level of accelerated
-
Lack of association between immunotherapy and improvement of survival for non-small cell lung cancer patients with hemodialysis: A nationwide retrospective cohort study Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-07 Kenji Sawa, Yasutaka Ihara, Takumi Imai, Akira Sugimoto, Hiroaki Nagamine, Koichi Ogawa, Kenji Nakahama, Yoshiya Matsumoto, Yoko Tani, Hiroyasu Kaneda, Shigeki Mitsuoka, Tomoya Kawaguchi, Ayumi Shintani
Background The number of patients undergoing hemodialysis continues to increase globally, and the incidence of cancer is high among these patients. Immune checkpoint inhibitors (ICIs) are widely used in patients with advanced cancer, especially non-small cell lung cancer (NSCLC); however, their effectiveness in hemodialysis patients is poorly documented. Methods This retrospective cohort study used
-
Sufficient multidisciplinary discussion can make patients’ outcomes better in the treatment for stage III non-small cell lung carcinoma. -Reply to Ohri et al. Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-03 Hiroyuki Adachi, Hiroyuki Ito, Tetsuya Isaka, Haruhiro Saito, Daisaku Yoshida, Tomoyuki Yokose, Aya Saito
Abstract not available
-
Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma Clin. Lung Cancer (IF 3.6) Pub Date : 2023-11-02 Qin Chen, Jing Wang, Xinyue Wang, Yan Yin, Xuan Wang, Zhenchun Song, Bin Xing, Yajing Li, Jingjing Zhang, Jianwen Qin, Richeng Jiang
Purpose A considerable portion of lung squamous cell cancer (LUSC) displays radiographic signs of cavitation. The cavitation of lesions is not accounted for in the prevailing Evaluation Criteria of Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or iRECIST in lung cancer. We hypothesized that cavitation might alter response assessment in these patients. Patients and Methods We performed
-
Barriers to Timely Lung Cancer Care in Early Stage Non-small Cell Lung Cancer and Impact on Patient Outcomes Clin. Lung Cancer (IF 3.6) Pub Date : 2023-10-31 Mina Pirzadeh, Madeline Lagina, Cameron Wood, Thomas Valley, Nithya Ramnath, Douglas Arenberg, Jane C. Deng
BACKGROUND Optimal time to treatment for early-stage lung cancer is uncertain. We examined causes of delays in care for Veterans who presented with early-stage non-small cell lung cancer (NSCLC) and whether workup time was associated with increased upstaging or all-cause mortality. METHODS We performed a retrospective analysis of Veterans referred to our facility with radiographic stage I or II NSCLC
-
-
-
Niraparib for the treatment of metastatic NSCLC in a patient with BRCA2 germinal mutation: a case report Clin. Lung Cancer (IF 3.6) Pub Date : 2023-10-29 Alessandro Inno, Vincenzo Picece, Giuseppe Bogina, Giulio Settanni, Valeria Viassolo, Matteo Salgarello, Stefania Gori
Mutations in the breast and ovarian cancer genes 1 and 2 (BRCA1 and BRCA2) occur approximately in 2% of non-small cell lung cancer (NSCLC). Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective in tumors with impaired BRCA1/BRCA2 function, including breast, ovarian, pancreatic, and prostate cancer, but their role in NSCLC is not yet defined. Here we report the case of a patient with advanced
-
A Phase II Trial of Pevonedistat and Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Clin. Lung Cancer (IF 3.6) Pub Date : 2023-10-26 Angel Qin, Leah Wells, Binu Malhotra, Shirish Gadgeel, Bryan J. Schneider, Nithya Ramnath, John D. Rice, Gregory P. Kalemkerian
Background Post-immunotherapy (IO) treatment options for stage IV non-small cell lung cancer (NSCLC)remain limited. Docetaxel alone or in combination with ramucirumab remains a standard of care, but response rates and survival benefit are suboptimal. Cullin-RING ligases (CRL) catalyze degradation of tumor suppressor proteins and are overactivated in NSCLC. Neddylation, which is catalyzed by the NEDD8
-
Long-Term Survival Analysis of Pleural Mesothelioma Patients Undergoing Surgery: Brief Report From a Tertiary Referral Centre Clin. Lung Cancer (IF 3.6) Pub Date : 2023-10-24 Riccardo Orlandi, Giovanni Leuzzi, Luigi Rolli, Michele Ferrari, Alessia Stanzi, Camilla Valsecchi, Ugo Pastorino
Objectives to date, no consensus has been reached on the surgical gold-standard in pleural mesothelioma (PM). We retrospectively reviewed our experience as a tertiary referral centre, to compare short- and long-term survival of PM patients undergoing different types of surgery. Methods in retrospective, observational, single-centre study, we analysed all the patients histologically diagnosed with PM